Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31071954 | 0.80 | ALDH1A1 (0.36) | KMT2AALDH1A1HPGD | |
| SCHEMBL21767445 | 0.80 | ALDH1A1 (0.36) | KMT2AALDH1A1HPGD | |
| SCHEMBL26049567 | 0.73 | ALDH1A1 (0.36) | KMT2AALDH1A1HPGD | |
| SCHEMBL23647808 | 0.71 | S1PR1 (0.33) | — | |
| SCHEMBL29866204 | 0.71 | S1PR1 (0.33) | — | |
| SCHEMBL6205091 | 0.70 | DPP4 (0.44) | — | |
| SCHEMBL24876469 | 0.68 | NR3C1 (0.38) | KMT2A | |
| SCHEMBL6204307 | 0.67 | IDO1 (0.46) | ALDH1A1 | |
| SCHEMBL22650329 | 0.67 | SLC6A2 (0.38) | — | |
| SCHEMBL23426186 | 0.67 | SLC6A2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | KMT2A 4216/4885ALDH1A1 1504/4885HPGD 3060/4885 |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | KMT2A 4216/4885ALDH1A1 1504/4885HPGD 3060/4885 |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | KMT2A 4216/4885ALDH1A1 1504/4885HPGD 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.